Docoh
Loading...
Sign up Log in

AIM AIM ImmunoTech

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Company profile

Ticker
AIM
Exchange
NYSE
Website
aimimmuno.com/
CEO
Thomas Equels
Employees
Incorporated
Delaware
Location
Florida
Fiscal year end
Dec 31
Sector
Manufacturing > Biological Product (except Diagnostic) Manufacturing
Industry (SIC)
Biological Products, (No Diagnostic Substances)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...
Former names
HEMISPHERX BIOPHARMA INC
SEC CIK
0000946644
Corporate docs
IRS number
520845822

AIM stock data

(
)

News

Pro users get this 30m faster
AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study
7 Apr 21
AIM ImmunoTech Announces Safety Data In First Cohort Of Phase 1 Clinical Study Investigating Intranasal Administration Of Ampligen As Potential Prophylaxis Or Treatment For COVID-19 And Other Respiratory Viral Diseases
7 Apr 21
AIM ImmunoTech Inc. (NYSE:AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM's drug Ampligen as an intranasal therapy, reporting no serious adverse events,
AIM ImmunoTech On Apr. 5 Approved Proposal From Polysciences For Manufacture Of AIM's Poly I And Poly C12U polynucleotides; Seperately Entered MArerial Transfer And Research Agreement With University of Cagliari Dipartimento di Scienze della Vita e dell'A
7 Apr 21
AIM ImmunoTech Inc. (“AIM” or “Company”) has recently entered into two agreements. On April 5, 2021, the Company approved a proposal from Polysciences Inc. (“Polysciences”)
AIM ImmunoTech Q4 EPS $(0.09) Up From $(0.33) YoY, Sales $42.00K Down From $50.00K YoY
31 Mar 21
AIM ImmunoTech Shares Spike Higher; Co Announces Addition Of Single-Agent Ampligen Arm To Cancer Center's Ongoing Study In Cancer Patients With COVID-19
22 Mar 21

Press releases

Pro users get this 30m faster
AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases
7 Apr 21
OCALA, Fla., April 07, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM's drug Ampligen as an intranasal
AIM ImmunoTech Reports 2020 Year-End Financial Results
31 Mar 21
OCALA, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update. 2020 Financial Highlights As of
AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center's Ongoing Study in Cancer Patients with COVID-19
22 Mar 21
OCALA, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) today announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer Center (Roswell Park) has approved a
AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th
11 Mar 21
AIM ImmunoTech to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
10 Mar 21

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

30 Mar 21
13 Apr 21
31 Dec 21

Financial summary

Financial statements Chart AIM financial data
Quarter (USD)
 Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 38.5M 38.5M 38.5M 38.5M 38.5M 38.5M
Cash burn (monthly) (positive/no burn) (positive/no burn) 1.72M 1.26M 951.33K 864K
Cash used (since last report) n/a n/a 5.93M 4.37M 3.29M 2.99M
Cash remaining n/a n/a 32.57M 34.13M 35.21M 35.51M
Runway (months of cash) n/a n/a 19.0 27.0 37.0 41.1

Beta Read what these cash burn values mean

Recent insider trades

AIM insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
25 Feb 21 Stewart Appelrouth Common Stock Buy Aquire P No No 2.35 10,638 25K 92,538
24 Feb 21 Equels Thomas K. Common Stock Buy Aquire P No No 2.26 11,062 25K 209,630
17 Dec 20 Equels Thomas K. Common Stock Buy Aquire P No No 1.72 14,535 25K 198,568
9 Dec 20 Ellen M Lintal Options Common Stock Grant Aquire A No No 1.85 75,000 138.75K 75,000
9 Dec 20 Iii Peter W. Rodino Options Common Stock Grant Aquire A No No 1.85 75,000 138.75K 75,000
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

AIM institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
 Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
 Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners
 Shares Value Change
Largest transactions
 Shares Bought/sold Change
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Baxter International • Pfizer • Canada • Astrazeneca • Novartis • Glaxosmithkline
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: adjudicated, admissible, airway, alfa, allocate, allocated, Amarex, atomized, augment, Barnard, BDO, began, Benedict, billion, bore, Bronze, Bulletin, career, Centre, CHDR, cisplatin, compelling, contradictory, cooperation, curb, deadly, deep, delivery, device, difficulty, distantly, Distinguished, dosage, draft, EC, epidemic, Equel, evolution, Flying, forging, fruitful, genomic, gravity, hamster, household, immaterial, inactivated, IND, inhalation, inhaler, IRB, Japanese, judge, Knighted, knowledge, Lab, Leiden, length, lethal, Leyden, Library, magnitude, MC, mice, military, mist, moderate, moment, mortality, mouse, MTA, NOL, notified, NV, OMP, owed, owing, particle, pathogenic, Perrigo, persistent, Philip, Pii, Pope, premier, Purple, Ransom, rare, redacted, redundancy, reinsurance, reopening, repeated, replicate, representation, Roane, Rochester, Scotland, Scrap, Shionogi, Simmaron, situation, societal, spectrum, sponsorship, Star, storage, surrendered, Syrian, temporarily, thousand, transcription, transpire, Treaty, trilateral, UMN, upper, Utah, vapor, Vietnam, vigorously, waiting, WIP, yearly
Removed: adam, adjacent, agree, alleviated, aspect, assisted, automatic, Avecia, Avenue, borrowed, bridge, Civil, claiming, commute, complaint, conserve, constructive, consuming, consummated, counter, County, cure, curtail, delivered, denying, diminishing, discretionary, dispute, Division, element, emerging, entering, exchanged, exercising, Failing, faith, fiduciary, fringe, gained, graduate, implementing, improve, initiating, intentionally, Irrevocable, legacy, netted, Nitto, Notwithstanding, omission, penalty, Philadelphia, practicable, practice, preapproval, prepay, prepayment, principle, producing, proper, pursuit, reexamined, requisite, restructuring, retrospectively, RSM, saving, secure, Shirley, spending, standpoint, stating, substitute, successor, suitable, supplement, Task, terminate, therefrom, thirty, title, transferred, unaffiliated, unencumbered, unrestricted, unutilized, warehouse, wholly
From filing 10-K 2020 FY

Financial reports

View all
10-K
2020 FY
Annual report
30 Mar 21
10-Q
2020 Q3
Quarterly report
12 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q/A
2020 Q1
Quarterly report (amended)
14 May 20
10-Q
2020 Q1
Quarterly report
13 May 20
10-K
2019 FY
Annual report
30 Mar 20
10-Q
2019 Q3
Quarterly report
14 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
15 May 19
10-K
2018 FY
Annual report
1 Apr 19

Current reports

View all
8-K
Other Events
9 Apr 21
8-K
Entry into a Material Definitive Agreement
7 Apr 21
8-K
Regulation FD Disclosure
23 Mar 21
8-K
AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center’s
22 Mar 21
8-K
Regulation FD Disclosure
10 Mar 21
8-K
Regulation FD Disclosure
8 Mar 21
8-K
Implementation Decision of the Committee
24 Feb 21
8-K
Other Events
5 Feb 21
8-K
AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen
29 Jan 21
8-K
Changes in Registrant's Certifying Accountant
22 Jan 21

Registration and prospectus

View all
424B5
Prospectus supplement for primary offering
18 Aug 20
S-8
Registration of securities for employees
3 Aug 20
424B5
Prospectus supplement for primary offering
15 Jun 20
424B5
Prospectus supplement for primary offering
10 Mar 20
424B5
Prospectus supplement for primary offering
3 Mar 20
424B4
Prospectus supplement with pricing info
26 Sep 19
S-1/A
IPO registration (amended)
24 Sep 19
S-1/A
IPO registration (amended)
24 Sep 19
S-1/A
IPO registration (amended)
23 Sep 19
S-1
IPO registration
6 Sep 19

Proxies

View all
DEF 14A
Definitive proxy
11 Aug 20
DEF 14A
Definitive proxy
20 Aug 19
DEF 14A
Definitive proxy
23 Apr 19
PRE 14A
Preliminary proxy
5 Apr 19
DEF 14A
Definitive proxy
3 Aug 18
PRE 14A
Preliminary proxy
19 Jul 18
DEF 14A
Definitive proxy
17 Jul 17
DEFA14A
Additional proxy soliciting materials
13 Jul 16
DEF 14A
Definitive proxy
26 Jun 16
PRER14A
Preliminary revised proxy
8 Jun 16

Other

View all
EFFECT
Notice of effectiveness
26 Sep 19
UPLOAD
Letter from SEC
25 Sep 19
CORRESP
Correspondence with SEC
23 Sep 19
CORRESP
Correspondence with SEC
23 Sep 19
CORRESP
Correspondence with SEC
23 Sep 19
UPLOAD
Letter from SEC
23 Sep 19
UPLOAD
Letter from SEC
11 Sep 19
CORRESP
Correspondence with SEC
5 Sep 19
EFFECT
Notice of effectiveness
15 Feb 19
CORRESP
Correspondence with SEC
10 Feb 19

Ownership

View all
4
AIM ImmunoTech / STEWART APPELROUTH ownership change
25 Feb 21
4
AIM ImmunoTech / THOMAS K. EQUELS ownership change
24 Feb 21
SC 13G/A
AIM ImmunoTech / Hudson Bay Capital Management ownership change
8 Feb 21
4
AIM ImmunoTech / THOMAS K. EQUELS ownership change
17 Dec 20
4
AIM ImmunoTech / III PETER W. RODINO ownership change
11 Dec 20
4
AIM ImmunoTech / ELLEN M LINTAL ownership change
11 Dec 20
4
AIM ImmunoTech / THOMAS K. EQUELS ownership change
13 Nov 20
4
AIM ImmunoTech / THOMAS K. EQUELS ownership change
3 Sep 20
4
AIM ImmunoTech / THOMAS K. EQUELS ownership change
21 Aug 20
4
AIM ImmunoTech / WILLIAM M MITCHELL ownership change
14 Aug 20

Patents

APP
Utility
Compositions for Cancer Therapy and Methods
24 Jun 20
One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately.

Reddit threads

View all